JLL Partners (“JLL”), a leading middle-market private equity firm, and Royal DSM, the global Life Sciences and Materials Sciences company, today announced the creation of a new company, which will be a leading global contract development and manufacturing organization (CDMO) for the pharmaceutical industry with anticipated sales of around USD 2 billion. It will be 51% owned by JLL and 49% by DSM. Download full release here.
JLL Partners Inc., a New York-based private-equity firm, agreed to buy a majority stake in vitamin-maker Royal DSM NV (DSM)’s pharmaceuticals business to create a new company in a deal valued at $2.6 billion. The unit will be rolled into Patheon Inc. (PTI), a Canada-based specialty-pharmaceuticals manufacturer controlled by JLL, the companies said in a joint statement today. The new entity is projected to have sales next year of about $2 billion. DSM shares gained as much as 3.7 percent in Amsterdam trading. Read the full article on Bloomberg here.